---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001486"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:46:34.289032+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M

## Summary
- Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.
- Out-licensing deals with Aries ($61M milestones), MycoMedica ($62M), Restoration Biologics ($82M).
- Lead candidate EB-003 confirmed oral bioavailability and brain exposure; pre-IND activities ongoing.
- Closed $5M public offering in 2024 to fund development.

## SEC filing metadata
- accession: 0001641172-25-001486
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/0001641172-25-001486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001486
- JSON: https://secwatch.observer/filing/0001641172-25-001486.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.